Marksans Pharma Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
2,235
- Stock Symbol
-
MARKSANS
- Investments
-
9
- Share Price
-
$3.20
- (As of Thursday Closing)
Marksans Pharma General Information
Description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Contact Information
Website
www.marksanspharma.comCorporate Office
- 11th Floor, Grandeur, Opposite Gundecha Symphony
- Off Veera Desai Extension Road, Oshiwara, Andheri West
- Mumbai, Maharashtra 400053
- India
Corporate Office
- 11th Floor, Grandeur, Opposite Gundecha Symphony
- Off Veera Desai Extension Road, Oshiwara, Andheri West
- Mumbai, Maharashtra 400053
- India
Marksans Pharma Stock Performance
As of 19-Nov-2026, Marksans Pharma’s stock price is $3.20. Its current market cap is $1.45B with 453M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.20 | $3.15 | $1.64 - $3.70 | $1.45B | 453M | 1.88M | $0.13 |
Marksans Pharma Financials Summary
As of 30-Sep-2026, Marksans Pharma has a trailing 12-month revenue of $366M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,456,422 | 717,014 | 1,122,814 | 749,230 |
| Revenue | 365,783 | 332,902 | 309,192 | 262,629 |
| EBITDA | 95,165 | 74,197 | 67,270 | 57,403 |
| Net Income | 60,377 | 47,293 | 45,008 | 37,893 |
| Total Assets | 453,885 | 409,199 | 378,730 | 321,482 |
| Total Debt | 48,370 | 36,393 | 37,633 | 29,266 |
Marksans Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Marksans Pharma Comparisons
Industry
Financing
Details
Marksans Pharma Competitors (15)
One of Marksans Pharma’s 15 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Aurobindo Pharma | Corporation | Hyderabad, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India |
Marksans Pharma Patents
Marksans Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220079894-A1 | Stable pharmaceutical compositions | Inactive | 11-Sep-2020 | ||
| WO-2008001389-A2 | Female contraceptive for transcervical delivery and its' preparation | Inactive | 27-Jun-2006 | ||
| WO-2008001389-A3 | Female contraceptive for transcervical delivery and its' preparation | Inactive | 27-Jun-2006 | A61K31/194 |
Marksans Pharma Signals
Marksans Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Marksans Pharma Investments & Acquisitions (9)
Marksans Pharma’s most recent deal was a Merger/Acquisition with ABCnow for . The deal was made on 20-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ABCnow | 20-Jul-2026 | Merger/Acquisition | Distributors (Healthcare) | ||
| QliniQ | 16-Jun-2026 | Merger/Acquisition | Medical Supplies | ||
| Teva pharm India (manufacturing Unit) | 19-Apr-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Tevapharm (Pharmaceutical Formulations Business) | 18-Apr-2023 | Merger/Acquisition | Pharmaceuticals | ||
| Access Healthcare (Media and Information Services (B2B)) | 06-Jun-2022 | Merger/Acquisition | Media and Information Services (B2B) |
Marksans Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.21 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Marksans Pharma Exits (1)
Marksans Pharma’s most recent exit was on 18-Jan-2008 from Hale Group. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Hale Group | 18-Jan-2008 | Completed |
|
Marksans Pharma Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| QliniQ | Oldenzaal, Netherlands | 2007 | |
| Relonchem | Widnes, United Kingdom | 2002 | |
| Time-Cap Labs | Farmingdale, NY | 1979 | |
| Bell's Healthcare | Widnes, United Kingdom | 1939 | |
| Access Healthcare (Media and Information Services (B2B)) | Dubai, United Arab Emirates |
Marksans Pharma FAQs
-
When was Marksans Pharma founded?
Marksans Pharma was founded in 1992.
-
Where is Marksans Pharma headquartered?
Marksans Pharma is headquartered in Mumbai, India.
-
What is the size of Marksans Pharma?
Marksans Pharma has 2,235 total employees.
-
What industry is Marksans Pharma in?
Marksans Pharma’s primary industry is Drug Discovery.
-
Is Marksans Pharma a private or public company?
Marksans Pharma is a Public company.
-
What is Marksans Pharma’s stock symbol?
The ticker symbol for Marksans Pharma is MARKSANS.
-
What is the current stock price of Marksans Pharma?
As of 19-Nov-2026 the stock price of Marksans Pharma is $3.20.
-
What is the current market cap of Marksans Pharma?
The current market capitalization of Marksans Pharma is $1.45B.
-
What is Marksans Pharma’s current revenue?
The trailing twelve month revenue for Marksans Pharma is $366M.
-
Who are Marksans Pharma’s competitors?
Evonile Pharma, Novartis, Torrent Pharmaceuticals, Aurobindo Pharma, and Biocon are some of the 15 competitors of Marksans Pharma.
-
What is Marksans Pharma’s annual earnings per share (EPS)?
Marksans Pharma’s EPS for 12 months was $0.13.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process